---
title: "Novo Nordisk responds to the restricted sales of \"weight loss miracle drug\" Wegovy in China: Global supply shortage, orderly supply launch in the Chinese market"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/207622467.md"
description: "Novo Nordisk responds to the limited sale of \"weight loss miracle drug\" Wegovy in China, stating that they will soon introduce the product to the Chinese market to meet the needs of a large number of obese patients. This drug is based on a GLP-1 receptor agonist and has been launched in over 10 countries worldwide, attracting widespread attention. Currently, Novo Nordisk has chosen to sell in limited quantities to address the high demand for this innovative drug in the market. Novo Nordisk China is working hard to increase the supply of GLP-1 class drugs"
datetime: "2024-07-01T01:47:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/207622467.md)
  - [en](https://longbridge.com/en/news/207622467.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/207622467.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/207622467.md) | [繁體中文](https://longbridge.com/zh-HK/news/207622467.md)


# Novo Nordisk responds to the restricted sales of "weight loss miracle drug" Wegovy in China: Global supply shortage, orderly supply launch in the Chinese market

On June 28th, according to market news, Novo Nordisk AS's "weight-loss miracle drug" Wegovy (Chinese brand name: Nuohoying) will adopt a limited sales strategy in the Chinese market. In response, Novo Nordisk China quickly stated that since the approval of Nuohoying, they have initiated the drug supply process and will soon introduce this important product to the Chinese market to benefit a large number of obese patients.

Nuohoying, Wegovy, with the main ingredient semaglutide, is an injectable solution based on a GLP-1 receptor agonist, widely recognized as an innovative therapy in the field of weight loss. Currently, the drug has been launched in over 10 countries globally, including China, and its significant weight loss effects have attracted widespread attention worldwide. However, in terms of supply strategy in the Chinese market, Novo Nordisk has chosen a limited sales approach to address the high demand for this innovative drug.

Facing the supply challenges brought about by the surge in market demand, Novo Nordisk China stated: the company is working to increase the product supply of GLP-1 class drugs. "We will responsibly distribute existing product supplies in the global market, following consistent standards, focusing on ensuring the continuity of patient medication and the accessibility of innovative drugs."

Keyword Reading: Novo Nordisk AS

### 相关股票

- [Novo Nordisk AS (NVO.US)](https://longbridge.com/zh-CN/quote/NVO.US.md)

## 相关资讯与研究

- [Omeros Turns Corner With Novo Deal, YARTEMLEA Launch](https://longbridge.com/zh-CN/news/281666535.md)
- [As the FDA Approves a Wegovy Pill, Should You Buy, Sell, or Hold Novo Nordisk Stock?](https://longbridge.com/zh-CN/news/270794581.md)
- [The High-Bandwidth Memory (HBM) Bottleneck Can Still Cause Micron's Stock to Soar](https://longbridge.com/zh-CN/news/281662827.md)
- [SpaceX Valuation at $2 Trillion: How It Surpasses Meta and Tesla?](https://longbridge.com/zh-CN/news/281611627.md)
- [07:00 ETBybit Alpha Trading Fiesta Returns with 600,000 USDT in Rewards](https://longbridge.com/zh-CN/news/281630273.md)